Overall, the regulation of GluN2A-NMDAR and AMPAR’s function by NX210c may represent an innovative therapeutic opportunity to ameliorate outcomes in the elderly and patients suffering from CNS disorders with disabling synaptic defects. This evidence concerns the gene GRIN2A and central nervous system disorder.